Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

MCM7 (minichromosome maintenance complex component 7)

Written2020-09Keli Lima, Eduardo Magalhães Rego, João Agostinho Machado-Neto
Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Department of Hematology, Hospital das Clènicas HCFMUSP, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil (KL, EMR); Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil (KL, JAM-N); kelilima@usp.br (KL); eduardo.rego@fm.usp.br (EMR); jamachadoneto@usp.br (JAM-N)

Abstract MCM7 belongs to the minichromosome maintenance (MCM) protein family, which compromises DNA helicases that play a key role in DNA replication and G1/S cell cycle progression. There are plenty of studies on MCM7 expression for cancer development and progression. Increased levels of MCM7 are consistently implicated in high aggressiveness characteristics and poor clinical outcomes in several cancer types. In the present review, the data on DNA/RNA, the protein encoded, and the implication of MCM7 as diagnostic, prognostic, and biological values in cancer are described.

Keywords MCM7; Cell cycle; DNA replication; G1/S Transition; Adrenocortical carcinoma; Adrenocorticotropin secreting tumors; Bladder cancer; Breast cancer; Cervical cancer; Colorectal cancer; Cutaneous diseases; Desmoid cancer; Endometrial cancer; Head and neck cancer; Hepatocellular carcinoma; Gastric cancer; Gliomas; Leukemia; Lymphoma; Lung cancer; Medulloblastoma; Meningiomas; Neuroblastoma; Pancreatic cancer; Pituitary adenoma; Prostate cancer; Renal cancer; Retinoblastoma; Squamous cell carcinoma; Synovial sarcoma; Thyroid cancer

(Note : for Links provided by Atlas : click)

Identity

Alias (NCBI)MCM2
CDC47
P85MCM
P1CDC47
PNAS146
PPP1R104
P1.1-MCM3
HGNC (Hugo) MCM7
HGNC Alias symbCDC47
PPP1R104
HGNC Alias nameprotein phosphatase 1, regulatory subunit 104
HGNC Previous nameMCM2
HGNC Previous nameminichromosome maintenance deficient (S. cerevisiae) 7
 MCM7 minichromosome maintenance deficient 7 (S. cerevisiae)
LocusID (NCBI) 4176
Atlas_Id 41323
Location 7q22.1  [Link to chromosome band 7q22]
Location_base_pair Starts at 100092728 and ends at 100100780 bp from pter ( according to GRCh38/hg38-Dec_2013)  [Mapping MCM7.png]
Fusion genes
(updated 2017)
Data from Atlas, Mitelman, Cosmic Fusion, Fusion Cancer, TCGA fusion databases with official HUGO symbols (see references in chromosomal bands)

DNA/RNA

Description The entire MCM7 gene is approximately 9.2 Kb (start: 100092728 and end: 100101940 bp; orientation: reverse strand). In the NCBI database (https://www.ncbi.nlm.nih.gov/gene), there are 3 transcript variants for CDC7 that encode for the 2 protein isoforms. The transcript variant 1 (transcript length: 2467 bp); encodes the longer protein, isoform 1 (719 aa). The transcript variant 2 (transcript length: 2996 bp) and 3 (transcript length: 2542 bp) encodes the short protein, isoform 2 (543 aa). Both transcript variants, 2 and 3, contain an additional internal segment that leads to translation initiation from an in-frame downstream AUG compared to transcript variant 1, which leads to a shorter N-terminus. In Ensembl database (http://www.ensembl.org/), there are ten additional transcript variants for MCM7, two are protein coding transcripts (ENST00000343023.10: 1968 bp and 389 aa, and ENST00000425308.5: 1497 bp and 183 aa), one is a nonsense-mediated mRNA decay (ENST00000491245.6: 648 bp and 83 aa) and seven are non-protein-coding transcripts.

Protein

 
  Figure 1. Schematic MCM7 protein structure. (A) MCM7 protein presents two isoforms (isoform 1: 719 aa, isoform 2: 543 aa) and contains a minichromosome maintenance (MCM) domain. The position of amino acids (aa) is indicated in the Figure. The 3D reconstitution of the isoform 1 of MCM7 protein was constructed using the Swiss-model platform (https://swissmodel.expasy.org/), and cartoon (B) and surface (C) versions of the protein are illustrated.
Description Two MCM7 isoforms are better described: the isoform 1 consists of 719 amino acids (aa), while isoform 2 consists of 543 aa, both isoforms present a conserved MCM domain in the C-terminal region. The schematic representation of the MCM7 isoforms are illustrated in Figure 1.
Expression Ubiquitous.
Localisation Cytoplasm and nucleus. The nuclear import of MCM proteins occurs as a complex.
Function MCM7 belongs to the minichromosome maintenance (MCM) protein family, which compromises DNA helicases important for initiating DNA replication and for cell cycle progression (Forsburg, 2008; Lo Sardo et al., 2017). This protein family consists of at least six members (MCM2-7) that have been implicated in the regulatory machinery to ensure DNA synthesis happens once per cell cycle. During the G1 phase of the cell cycle, the MCM complex is inactive around the double DNA strand at the replication origins. In the S phase of the cell cycle, there is the recruitment of helicase cofactors, CDC45 and GINS, for the MCM complex (forming the CMG complex) that activates its activity, translocating it in the 3' to 5' direction along the DNA enabling the replisome assembly. The head-to-head configuration of the MCM complexes provides bidirectional DNA synthesis (Hyrien, 2016). Although uncomplexed MCM7 did not present ATPase or DNA helicase activity, it plays an essential for DNA helicase activity of the MCM complex (Figure 2). MCM7 expression is regulated by E2F transcription factors under growth factor stimulation by PI3K/AKT/ GSK3B / CCND1 / RB1 axis (Ishimi, 2018; Suzuki et al., 1998; Yoshida and Inoue, 2004). MCM7 is a marker of cell proliferation and its aberrant expression contributes to tumor development and progression (Honeycutt et al., 2006).
 
  Figure 2. Model for MCM7 function in DNA replication. MCM7 is a component of minichromosome maintenance (MCM) complex (MCM2-7), forming a hexameric ring that binds to DNA and acts as a replication licensing. The recruitment of CDC45 and GINS is required for helicase activity of the complex (CMG complex). Upon DNA unwinding, occurs the formation of replication forks in the double stranded DNA at origin and DNA synthesis by the recruitment of DNA polymerases.
Homology MCM7 has high homology among different species (Table 1).
Table 1. Comparative identity of human MCM7 with other species
% Identity for: Homo sapiens BIRC7SymbolProteinDNA
vs. P. troglodytesMCM7 99.9 99.4
vs. M. mulattaMCM7 98.4 96.4
vs. C. lupus MCM7 96.2 88.7
vs. B. taurus MCM7 96.4 89.3
vs. M. musculus Mcm7 92.8 86.9
vs. R. norvegicus Mcm7 94.3 87.1
vs. X. tropicalis mcm7 84.8 74.1
vs. D. rerio mcm7 80.8 73.6
vs. D. melanogaster Mcm7 67.5 63.7
vs. A. gambiae AgaP_AGAP005800 67.0 64.2
vs. C. elegans mcm-7 52.5 54.6
vs. S. cerevisiae MCM7 50.1 51.2
vs. K. lactis KLLA0E23189g 52.2 52.1
vs. E. gossypii AGOS_ADR041W 50.7 54.0
vs. S. pombe mcm7 50.8 51.7
vs. M. oryzae MGG_09300 50.8 54.6
vs. N. crassa NCU08119 52.4 56.4
vs. A. thaliana PRL 52.4 53.7
vs. O. sativa Os12g0560700 50.9 53.1

(Source: http://www.ncbi.nlm.nih.gov/homologene)

Mutations

Somatic Recurrent mutations in the MCM7 gene are rare. A total of 596 out of 47005 (1.3%) tested samples presented MCM7 genetic alterations (mutations, amplifications, deep deletions, and multiple alterations), as reported on cBioPortal (http://www.cbioportal.org). A total of 218 somatic mutations (0.5% of the samples) was found: 170 missense substitutions, 42 truncating, 4 inframe, and 2 other mutations. In COSMIC (Catalogue of Somatic Mutations in Cancer; http://cancer.sanger.ac.uk/cancergenome/projects/cosmic) data base, a total of 465 (1.2%) unique samples presenting MCM7 mutations were found among the 37667 samples tested, being 200 missense substitutions, 81 synonymous substitutions, 28 nonsense substitutions, 11 frameshift deletions, 3 frameshift insertions, 2 inframe deletions and 1 inframe insertion, and 60 other mutations.

Implicated in

  
Entity Adrenocortical carcinomas
Note MCM7 was identified as a potential diagnosis marker for distinguishing benign tumors from malignant adrenocortical tumors (Aporowicz et al., 2019).
Garbicz and colleagues (Garbicz et al., 2017) reported a significant increase of MCM7 expression in ACTHomas. In addition, MCM7 was ubiquitously overexpressed in Crooke cell adenomas and a combination of MCM7 and MIR106B - MIR25 expressions accurately differentiated invasive from non-invasive tumors and predicted postoperative tumor recurrence/progression.
  
  
Entity Bladder cancer
Note Atypical inverted papilloma presented increased MCM7 levels compared to typical papilloma, which was associated with higher proliferative activity induced by HPV infection. In addition, MCM7 expression was observed predominantly in the nucleus and, to a lesser extent, weakly in the cytoplasm (Shigehara et al., 2011a). In another study, the authors reported that the MCM7 expression in normal bladder mucous or HPV-negative bladder tissues was lower compared to HPV-positive tumors (Shigehara et al., 2011b). In a papillomavirus-associated bladder carcinoma case study, it was shown that MCM7 was highly expressed both in the basal cells of the condyloma tissue and in the basal layer of the tumor tissues (Kawaguchi et al., 2012). In a multicenter bladder cancer cohort (576 patients), MCM7 expression was an independent prognostic factor for disease progression (Fristrup et al., 2013).
Higher MCM7 expression was found in T24R2, a cisplatin-resistant bladder cancer cell line compared to T24, a cisplatin-sensitive bladder cancer cell line, suggesting a potential role for MCM7 in chemoresistance (Kim et al., 2016).
  
  
Entity Breast cancer
Note The expression of MCM7 was significantly higher in tumor than in adjacent non-tumor tissues, suggesting a potential role for this protein in the tumor development and progression (Lu et al., 2011; Song et al., 2006). In MCF-7 breast cancer cells, MCM7 participates in the MYB network and it was up-regulated by exposure to estradiol (Wu et al., 2012). Treatment with cantharidin inhibits the expression of MCM7, reducing cell proliferation, in MCF-7 cells (Zhang and Yan, 2015). In addition, the downregulation of MCM7 upregulated γH2AX (phosphorylated H2AX) in tamoxifen-resistant MCF7 and T47D breast cells (Liang et al., 2017).
  
  
Entity Cervical cancer
Note MCM7 interacts with E6 viral protein from HPV, which may be implicated in chromosomal abnormalities and cell transformation (Kukimoto et al., 1998). In cervical lesions associated with HPV-16, MCM7 expression was higher in intraepithelial lesions, and the highest levels were observed in cancer (Brake et al., 2003). Similarly, the expression of MCM7 presented a predictive value of cervical cancer severity with 94.0% sensitivity, 56.5% specificity, 88.8% positive predictive value, and 72.2% negative predictive value (Zhang et al., 2013).
  
  
Entity Colorectal cancer
Note MCM7 expression was an independent prognostic factor for colorectal cancer, and MCM7-positive tumors correlated with increased metastasis rates (Nishihara et al., 2008). High MCM7 expression was also associated with adverse clinical outcome in colorectal cancer patients who underwent surgery for the primary tumor (Pillaire et al., 2010). In agreement, MCM7-positive Dukes' C colorectal cancer patients presented lower overall survival and event-free survival (Ishibashi et al., 2014). Using quantitative PCR, Shi and colleagues (Shi et al., 2018) reported that MCM7 is one of the main genes involved in colorectal cancer progression. Recently, a meta-analysis has indicated MCM7 as a potential biomarker for colorectal cancer (Long et al., 2016).
Using a cohort of 13 anal cancer patients treated with radiation or without additional chemotherapy, Bruland and colleagues (Kreuter et al., 2010) described that the MCM7 protein was associated with better relapse-free survival and cancer-specific survival. The authors also highlighted that MCM7 may be regulated by the transcription factor E2F and induced by HPV. In anal intraepithelial high-grade neoplasm, the MCM protein family, including MCM7, was a marker of high-grade lesions and HPV-DNA load (Kreuter et al., 2010).
  
  
Entity Cutaneous diseases
Note Using malignant and premalignant cultured cells from cutaneous diseases, Hiraiwa and colleagues (Hiraiwa et al., 1998) reported that MCM7 expression presented good correlations with clinical, microscopic, and biological malignancy characteristics.
  
  
Entity Desmoid cancer
Note Using microarray analysis, low MCM7 was observed in desmoid tumors, which may be associated with the reduced mitotic activity observed in this kind of tumors (Ferenc et al., 2010).
  
  
Entity Endometrial cancer
Note High MCM7 was a reliable marker for the diagnosis of endometrial carcinoma, which was also associated with high histological grade and poor survival outcomes (multivariate analysis) (Li et al., 2005). Similarly, MCM7 expression was upregulated in endometrial cancer compared to the normal adjacent tissues (Zhao et al., 2012).
  
  
Entity Head and neck cancer
Note Microarray analysis identified MCM7, among the six genes overexpressed in hypopharyngeal tumors, which was also associated with disease aggressiveness (Cromer et al., 2004). Similarly, MCM7 was increased in salivary tumors compared to normal salivary tissues and the high MCM7 expression was associated with advanced stage, invasion of adjacent tissue, invasion of the nerve, and poor clinical outcomes (Wen et al., 2018).
Using a murine model of head and neck squamous cell carcinoma, MCM7 was found as a potential biomarker for distinguishing HPV-positive and HPV-negative tumors (Strati et al., 2006).
  
  
Entity Hepatocellular carcinoma
Note MCM7 expression was higher in hepatocellular carcinoma compared with non-tumor liver samples (Iizuka et al., 2006; Karavias et al., 2016; Qu et al., 2017; Wang et al., 2019; Yen et al., 2016). MCM7-positive hepatocellular carcinoma was associated with hepatitis, intrahepatic metastasis, vascular invasion, cell differentiation, tumor size, and shorter overall survival (Qu et al., 2017; Wang et al., 2019; Zhou et al., 2012).
In a cohort of 1300 cases of HBV-positive hepatocellular carcinoma, 1344 HBV-persistent, and 1344 individuals with natural HBV clearance, the AG/GG genotypes of the MCM7 polymorphism, rs999885, presented a decreased risk of chronic HBV infection in natural HBV clearance subjects. On the other hand, AG/GG genotypes negatively impacted the risk for the development of hepatocellular carcinoma in HBV persistent carriers (Liu et al., 2012a).
In univariate analysis, the G/G genotype of polymorphism in MCM7, rs2070215, impacted the risk for the development of the disease in a cohort containing 1019 hepatocellular carcinoma patients and 1138 healthy individuals (Nan et al., 2016). In hepatoma cells, MCM7 was downregulated by histone deacetylase inhibitor SAHA (Yang et al., 2015).
MCM7 shRNA lentivirus-mediated silencing reduced malignant behavior, suppressing proliferation, cell cycle progression, survival, and invasiveness, in MHCC-97H cells (Liu et al., 2015). Similarly, MCM7 silencing significantly reduced cellular proliferation in vitro and hepatocellular carcinoma tumorigenicity in vivo (Qu et al., 2017).
Using bioinformatics tools, MCM7 gene expression was identified as a potential biomarker for diagnosis and prognosis in hepatocellular carcinoma (Liao et al., 2018b; Liu et al., 2019). MCM7 expression was found to be a complementary and more effective prognostic marker compared to alpha-fetal protein in hepatocellular carcinoma (Xiang et al., 2019; Yu et al., 2018). Therefore, MCM7 was also identified as a protein with clinical relevance in hepatocellular carcinoma by PCT-SWATH (pressure-cycling technology applied to sequential window acquisition of all theoretical mass spectra) (Zhu et al., 2019).
Arsenic trioxide reduced MCM7 expression, which recapitulates the effects of MCM7 silencing on tumor suppression murine models of hepatocellular carcinoma, suggesting that arsenic trioxide may benefit from the treatment of this disease (Wang et al., 2019).
  
  
Entity Gastric cancer
Note Using array comparative genomic hybridization, the amplification of 7q22.1 was observed in samples from gastroesophageal adenocarcinomas, and despite the positive correlation between the expression of MCM7 mRNA and protein, no association was observed with the genomic data (van Dekken et al., 2009).
MCM7 expression was upregulated in tumors compared to non-tumor gastric tissues, and its nuclear expression was associated with advanced age and poor disease-specific survival. In normal gastric epithelial tissue, MCM7 was strictly expressed in the proliferative compartment (Kang et al., 2014). Of note, the combination of MCM7 and Ki-67 was a more sensitive proliferation marker to identify esophageal cancer, gastric carcinoma, and precancerous lesions (Huber et al., 2015; Yang et al., 2018).
MCM7 knockdown, by siRNA, suppressed cell proliferation, colony formation, and invasion, and induced late apoptosis in gastric cancer cell lines (Kang et al., 2014).
  
  
Entity Gliomas
Note Bioinformatics tools identified that the genomic region containing the MCM7 gene was amplified in more than 80% of the present cases and quantitative PCR confirmed the upregulation of MCM7 in glioblastomas compared to normal tissues (Erkan et al., 2014). In grade II-IV gliomas, increasing MCM7 expression was an independent predictor of poor overall survival (Hua et al., 2014). Using immunohistochemistry, MCM7 was found to a better marker for identifying cells into cell cycle progression than MKI67 (Ki-67) and PCNA in glioblastoma (Facoetti et al., 2006).
In glioblastoma models, siRNA-mediated MCM7 knockdown reduced cell proliferation and inhibited tumor growth in the xenograft and orthotopic glioblastoma models in rats (Erkan et al., 2014).
  
  
Entity Leukemia
Note The single nucleotide polymorphisms in MCM7, rs2070215, rs1534309, rs2307355, and rs17447273, were not associated with AML risk (103 AML patients and 241 healthy individuals), but the rs2070215 significantly associated with AML relapse and the C/C genotype of rs1534309 positively impacted on the survival of AML patients (Lee et al., 2017). The impact of single nucleotide polymorphisms on MCM7, rs2070215, rs1527423, and rs1534309, was also investigated in a cohort of 281 acute myeloid leukemia patients and 405 healthy individuals, and the allele C of rs2070215 presented an increased frequency in AML patients (Tripon et al., 2020). In addition, among the eight different haplotypes, two (G/A/T and C/A/T for rs1534309/rs1527423/rs2070215, respectively) were associated with AML risk, regardless of age and gender (Tripon et al., 2020).
Higher MCM7 expression was observed at relapse when compared to the time of diagnosis in MLL-rearranged pediatric acute myeloid leukemia (Verboon et al., 2016). In chronic myeloid leukemia cells, K562, MCM7 is highly expressed and its silencing by siRNA exerts anti-proliferative and pro-apoptotic effects (Tian et al., 2017)
  
  
Entity Lymphoma
Note In Hodgkin's lymphoma, MCM7 is highly expressed in asymptomatic patients. High MCM7 expression was associated with greater age, advanced stage of the disease, and negatively impacted overall survival in multivariate analysis (Marnerides et al., 2011). Using immunohistochemistry, MCM7 was found to be more frequently positive in primary cutaneous T-cell lymphoma samples compared to benign inflammatory dermatosis, and it was also correlated with Ki-67 and MCM3 expression (Jankowska-Konsur et al., 2015).
In lymphoproliferative skin disorders of T cells, MCM7 levels were observed in a greater expression of mycosis fungoides IIB--V and lymphomatoid papulosis compared to parapsoriasis in plaque and mycosis fungoides stage I-IIA (Gambichler et al., 2008).
  
  
Entity Lung cancer
Note Fujioka and colleagues (Fujioka et al., 2009), evaluating MCM7 and Ki-67 expressions in lung adenocarcinoma, found that MCM7 may be an independent prognostic marker, especially in early-stage tumors. MCM7-positive cells were absent in non-neoplastic alveolar epithelia and it was significantly higher in the peripheral area of the tumor (Fujioka et al., 2009). High scores for MCM7 expression were correlated with male gender, high histological grade, worse histological subtype, and increased tumor size and worse prognosis. Latterly, the same research group has shown how MCM7 expression was decisive for the creation of a prognostic score, based on proteins expressed in different phases of the cell cycle. Thus, the scores containing proteins expressed in G1/S (MCM7+/Ki-67+/Geminin+) and S/G2/M (MCM7+/ AURKA +/p-Histone H3S10+) presented worse clinical outcomes than MCM7-negative patients (G0) (Haruki et al., 2012).
In agreement, another study reported that MCM7 expression was significantly higher in lung cancer tissues, and its high expression correlated with poor prognosis in non-small cell lung cancer (Toyokawa et al., 2011). The authors also showed that combination therapy of histone deacetylase inhibition by a novel HDAC inhibitor, YF454A, with erlotinib to overcome EGFR -TKI resistance in in vitro and in vivo non-small cell lung cancer growth, by blocking MCM7 expression (Toyokawa et al., 2011).
In squamous cell carcinoma and lung adenocarcinoma, MCM7 levels in bronchial brushings were correlated with patient gender, tumor type, and tumor location (Liu et al., 2012b), indicating that MCM7 may be used as a protein marker for the early detection of bronchial brushing lung cancer (Liu et al., 2014). Recently, the role of MCM7 as a diagnosis marker for lung cancer has been confirmed by employing the Granger causality test (Fan et al., 2019).
Zhong and colleagues (Zhong et al., 2014a; Zhong et al., 2014b) reported that positive MCM7 expression was associated with positive NEK2 and Ki-67 expression, which was an independent prognostic factor for survival in resected non-small cell lung cancer patients, and the combined expression of MCM7/Ki-67 with NEK2 improved prognostic prediction, in which patients who had positive NEK2 expressions and positive MCM7/Ki-67 presented a lower survival rate than patients with negative expressions for these markers (Zhong et al., 2014a; Zhong et al., 2014b).
In non-small cell lung cancer cells, MCM7 phosphorylation was regulated by RACK1 through the MCM7/RACK1/AKT complex, resulting in an increase of the oncogenic potential of these cells (Fei et al., 2017). MCM7 expression had also been correlated with LMNB2 levels, and the high expression of both proteins was correlated with high tumor TNM stage, moderate-poor differentiation, and shorter overall survival of non-small cell lung cancer patients (Ma et al., 2017). Lo Sardo and colleagues (Lo Sardo et al., 2017) added novel insights for MCM7-mediated oncogenic pathways in lung cancer, by the interaction of MCM7 and YAP1 / TAZ, which impacted cell proliferation by CDKN1A inhibition.
  
  
Entity Medulloblastoma
Note MCM7 overexpression increased anchorage-independent cell growth, migration, and invasion in medulloblastoma cells (Lau et al., 2010).
  
  
Entity Meningioma
Note MCM7 was highly expressed in meningioma compared to arachnoid tissues (Saydam et al., 2010), suggesting a potential role for this protein as a diagnostic marker. Similar findings were observed in recurrent meningiomas compared with non-recurrent meningiomas and the ROC curve indicated that MCM7 expression had a high sensitivity for disease recurrence (Winther and Torp, 2017). A higher percentage of MCM7-positive cells was also associated with reduced recurrence-free survival in multivariate analysis (Winther and Torp, 2017).
  
  
Entity Neuroblastoma
Note In neuroblastoma, MCM7 was found to be a target of MYCN transcription factor, once it is highly expressed in tumors with MYCN amplification (Shohet et al., 2002). In contrast, another study indicated that MCM7 overexpression is not necessarily correlated with MYCN amplification or an aggressive clinical course in neuroblastoma (Tsai et al., 2004).
Functional assays using a neuroblastoma cell line with inducible MYCN expression indicated that the increased rate of cells entering the S-phase and enhancing DNA replication machinery may be associated with the expression of MCM7 (Koppen et al., 2007).
  
  
Entity Ovarian cancer
Note In a cohort of 342 ovarian cancer patients, increased MCM7 expression was observed in high-grade serous tissues (Ota et al., 2011). Similar findings were reported by Kobierzycki and colleagues (Kobierzycki et al., 2013). In contrast, higher MCM7 expression was associated with better progression-free survival (Ota et al., 2011).
  
  
Entity Pancreatic cancer
Note Using microarray and immunohistochemistry analysis, high MCM7 expression was found in samples from pancreatic ductal adenocarcinoma patients (Grutzmann et al., 2004; Liang et al., 2014). In agreement, the MCM family, including MCM7, has been upregulated in pancreatic tumor tissues (Liao et al., 2018a).
In a retrospective cohort of pancreatic neuroendocrine neoplasm patients (n=156), the high expression of MCM7 was significantly associated with larger tumor size, non-functioning tumor, high grade, and TNM stage, and it was an independent prognostic factor for tumor progression (Ban et al., 2019).
  
  
Entity Pituitary adenoma
Note High nuclear MCM7 expression was associated with a shorter recurrence/progression-free survival in a cohort of 97 pituitary adenoma patients. Moreover, among patients with invasive tumors, high MCM7 identified those with the highest risk of recurrence/progression (Coli et al., 2016).
  
  
Entity Prostate cancer
Note Comparing MCM7 and Ki-67 expression as proliferation markers in prostate cancer, MCM7 was a better discriminatory marker for proliferation between benign epithelium, prostatic intraepithelial neoplasia, and invasive adenocarcinoma (Levesque et al., 2007; Majid et al., 2010; Padmanabhan et al., 2004).
MCM7 amplification or overexpression was associated with relapse, local invasion, and worse degree of the tumor (Ren et al., 2006). In prostate cancer patients treated with prostatectomy, high MCM7 was associated with a high Gleason score and was an independent shorter progression-free survival factor (Laitinen et al., 2008). Similar findings were reported by Tolonem and colleagues (Tolonen et al., 2011).
Evaluating cell proliferation and apoptosis profile in prostate aging in adult male Wistar rats, MCM7 was identified as a promising marker for the early detection of pre-malignant diseases (Gonzaga et al., 2017).
In DU145 cells, constitutive MCM7 expression resulted in marked DNA synthesis, cell proliferation, and invasion in vitro assays, and larger tumors and reduced mice survival in vivo assay (Ren et al., 2006). In agreement, MCM7 inhibition decreased tumor volume, metastases, and improved survival in xenograft DU145 and PC3 tumors mice (Shi et al., 2010).
  
  
Entity Renal cancer
Note The levels of expression of the members of the MCM family, including MCM7, were higher in renal cell carcinoma compared to the paired adjacent normal tissue. Primary renal cell carcinoma patients overexpressing two or more MCM-related genes and metastatic renal cell carcinoma patients overexpressing three or more MCM-related genes presented shorter disease-free survival (Zhong et al., 2017).
  
  
Entity Retinoblastoma
Note Using data-mining tools and validation by real-time RT-PCR and tissue microarrays in retinoblastoma and normal human retina samples, MCM7 was identified as a potential therapeutic target in retinoblastoma (Yang et al., 2008).
  
  
Entity Squamous cell carcinomas
Note Using a murine model with deregulated MCM7 expression on the basal layer of the epidermis, Honeycutt and colleagues (Honeycutt et al., 2006) concluded that MCM7 actively contributes to the formation of tumors, progression and malignant conversion of squamous cell carcinomas of the skin.
Increased MCM7 expression was associated with lymph node metastasis and high tumor grade in precancerous lesions and oral squamous cell carcinoma (Feng et al., 2008). In agreement, MCM7 expression was highly expressed in dysplasias and oral squamous cell carcinoma compared to normal epithelia, and its aberrant expression was associated with high histological grade, poorly differentiated tumors, and poor survival outcomes (Tamura et al., 2010).
In oesophageal squamous cell carcinoma, MCM7 was also associated with histological factors, tumor depth, lymph node metastasis, tumor stage, and G9a expression. Double-positive expression for EHMT2 (G9a) and MCM7 oesophageal squamous cell carcinoma patients (G9a+/MCM7+) presented shorter survival compared to those with low G9a or MCM7 expression (G9a-/MCM7-), (G9a+/MCM7-), (G9a-/MCM7+) (Zhong et al., 2015). Recently, Qiu and colleagues (Qiu et al., 2017) have reported that MCM7 is amplified in 12% of esophageal squamous cell carcinomas and > 4% of head and neck squamous cell carcinomas and stomach carcinomas patients from the TCGA data. MCM7 overexpression was confirmed in three GEO independent data sets for esophageal cancer. MCM7 silencing by siRNAs inhibited cell proliferation, colony formation, and migration in KYSE510 and EC9706 cells. MCM7 depletion also suppressed AKT/mTOR activation, and cell cycle-related regulatory proteins, CCND1, CCNE2, and CDK2 (Qiu et al., 2017).
MCM7 expression significantly correlated with Ki-67, BMI1, and CCNE1 expression, and MCM4 and MCM7 were sensitive proliferation markers in esophageal carcinoma and precancerous lesions (Choy et al., 2016). Using bioinformatics analysis of gene expression data, Wang and colleagues (Wang et al., 2015) highlighted that MCM7 belongs to critical genes for head and neck squamous cell carcinoma.
In laryngeal squamous cell carcinoma, MCM7 expression was associated with EGFR (HER1) expression, and its high expression increased risk for disease progression, benign an independent prognostic factor overall survival, and progression-free survival (Almadori et al., 2017). In addition, MCM7 expression presented a strong correlation with Ki-67 in laryngeal squamous cell cancer (Nowinska et al., 2016).
  
  
Entity Synovial sarcoma
Note MCM7 was found to be a target of MYCN in synovial sarcoma (Somers et al., 2007).
  
  
Entity Thyroid cancer
Note Using cDNA array, MCM7 upregulation was observed in malignant thyroid neoplasms compared to benign thyroid neoplasms, being more expressed in high graded and locally invasive tumors. MCM7 combined with MCM5 and RAD9A mRNA levels showed 98.2% sensitivity and 65.7% specificity as a predictor of malignancy (Kebebew et al., 2006). In anaplastic thyroid carcinoma cells, MCM7 was overexpressed compared to normal thyroid cells, which was related to TP53 activity (Guida et al., 2005).
  

To be noted

The prognostic value and biological function of MCM7 for oncogenesis have been extensively studied in several types of cancer. In general, increased levels of MCM7 are implicated in poor clinical outcomes. In addition, functional studies have indicated that high MCM7 expression promoted cell cycle progression, proliferation, migration, and invasion in in vitro and in vivo studies.
Acknowledgments: This study was supported by the grant #2019/23864-70, São Paulo Research Foundation (FAPESP), and grant #402587/2016-2, Conselho Nacional de Desenvolvimento Cientèfico e Tecnológico (CNPq). The authors thank Fernanda T. Udinal, from the Hemocentro Foundation of Ribeirão Preto, São Paulo, Brazil, for the English language review.

Bibliography

Minichromosome maintenance protein 7 and geminin expression: Prognostic value in laryngeal squamous cell carcinoma in patients treated with radiotherapy and cetuximab
Almadori G, Lauriola L, Coli A, Bussu F, Gallus R, Scannone D, Valentini V, Paludetti G, Carey TE, Ranelletti FO
Head Neck 2017 Apr;39(4):684-693.
PMID 28032719
 
Minichromosome Maintenance Proteins MCM-3, MCM-5, MCM-7, and Ki-67 as Proliferative Markers in Adrenocortical Tumors
Aporowicz M, Czopnik P, Kubicka E, Piotrowska A, Dziegiel P, Bolanowski M, Domoslawski P
Anticancer Res 2019 Mar;39(3):1151-1159.
PMID 30842144
 
High minichromosome maintenance protein 7 proliferation indices: a powerful predictor of progression in pancreatic neuroendocrine neoplasms without distant metastasis at the time of surgery
Ban X, Yan J, Yu S, Lu Z, Chang X, Jia C, Gao C, Shao H, Wu Y, Mao X, Zhang Y, Li Y, Chen J
Hum Pathol 2019 Mar;85:101-111.
PMID 30447299
 
Comparative analysis of cervical cancer in women and in a human papillomavirus-transgenic mouse model: identification of minichromosome maintenance protein 7 as an informative biomarker for human cervical cancer
Brake T, Connor JP, Petereit DG, Lambert PF
Cancer Res 2003 Dec 1;63(23):8173-80.
PMID 14678972
 
MCM4 and MCM7, potential novel proliferation markers, significantly correlated with Ki-67, Bmi1, and cyclin E expression in esophageal adenocarcinoma, squamous cell carcinoma, and precancerous lesions
Choy B, LaLonde A, Que J, Wu T, Zhou Z
Hum Pathol 2016 Nov;57:126-135.
PMID 27476776
 
Minichromosome maintenance protein 7 as prognostic marker of tumor aggressiveness in pituitary adenoma patients
Coli A, Asa SL, Fadda G, Scannone D, Chiloiro S, De Marinis L, Lauretti L, Ranelletti FO, Lauriola L
Eur J Endocrinol 2016 Mar;174(3):307-14.
PMID 26620390
 
Identification of genes associated with tumorigenesis and metastatic potential of hypopharyngeal cancer by microarray analysis
Cromer A, Carles A, Millon R, Ganguli G, Chalmel F, Lemaire F, Young J, Dembélé D, Thibault C, Muller D, Poch O, Abecassis J, Wasylyk B
Oncogene 2004 Apr 1;23(14):2484-98.
PMID 14676830
 
Depletion of minichromosome maintenance protein 7 inhibits glioblastoma multiforme tumor growth in vivo
Erkan EP, Ströbel T, Lewandrowski G, Tannous B, Madlener S, Czech T, Saydam N, Saydam O
Oncogene 2014 Sep 25;33(39):4778-85.
PMID 24166506
 
Minichromosome maintenance protein 7: a reliable tool for glioblastoma proliferation index
Facoetti A, Ranza E, Benericetti E, Ceroni M, Tedeschi F, Nano R
Anticancer Res Mar-Apr 2006;26(2A):1071-5.
PMID 16619508
 
Extracting predictors for lung adenocarcinoma based on Granger causality test and stepwise character selection
Fan X, Wang Y, Tang XQ
BMC Bioinformatics 2019 May 1;20(Suppl 7):197.
PMID 31074380
 
RACK1 promotes lung cancer cell growth via an MCM7/RACK1/ Akt signaling complex
Fei L, Ma Y, Zhang M, Liu X, Luo Y, Wang C, Zhang H, Zhang W, Han Y
Oncotarget 2017 Jun 20;8(25):40501-40513.
PMID 28465488
 
Expression of Mcm7 and Cdc6 in oral squamous cell carcinoma and precancerous lesions
Feng CJ, Li HJ, Li JN, Lu YJ, Liao GQ
Anticancer Res Nov-Dec 2008;28(6A):3763-9.
PMID 19189662
 
Minichromosome maintenance (MCM) and AgNOR proteins expression in desmoid tumours: a tissue microarray analysis
Ferenc T, Kopczyński J, Stalińska L, Tosik D, Sidor M, Lopaczyńska D, Kulig A, Dziki A, Sygut J
Folia Histochem Cytobiol 2010 Dec;48(4):581-8.
PMID 21478101
 
The MCM helicase: linking checkpoints to the replication fork
Forsburg SL
Biochem Soc Trans 2008 Feb;36(Pt 1):114-9.
PMID 18208397
 
Multicenter validation of cyclin D1, MCM7, TRIM29, and UBE2C as prognostic protein markers in non-muscle-invasive bladder cancer
Fristrup N, Birkenkamp-Demtröder K, Reinert T, Sanchez-Carbayo M, Segersten U, Malmström PU, Palou J, Alvarez-Múgica M, Pan CC, Ulhøi BP, Borre M, Ørntoft TF, Dyrskjøt L
Am J Pathol 2013 Feb;182(2):339-49.
PMID 23201130
 
Expression of minichromosome maintenance 7 (MCM7) in small lung adenocarcinomas (pT1): Prognostic implication
Fujioka S, Shomori K, Nishihara K, Yamaga K, Nosaka K, Araki K, Haruki T, Taniguchi Y, Nakamura H, Ito H
Lung Cancer 2009 Aug;65(2):223-9.
PMID 19144445
 
Expression of proliferation markers and cell cycle regulators in T cell lymphoproliferative skin disorders
Gambichler T, Bischoff S, Bechara FG, Altmeyer P, Kreuter A
J Dermatol Sci 2008 Feb;49(2):125-32.
PMID 17826963
 
Increased expression of the microRNA 106b~25 cluster and its host gene MCM7 in corticotroph pituitary adenomas is associated with tumor invasion and Crooke's cell morphology
Garbicz F, Mehlich D, Rak B, Sajjad E, Maksymowicz M, Paskal W, Zieliński G, Wńodarski PK
Pituitary 2017 Aug;20(4):450-463.
PMID 28432562
 
Profile of cell proliferation and apoptosis activated by the intrinsic and extrinsic pathways in the prostate of aging rats
Gonzaga ACR, Campolina-Silva GH, Werneck-Gomes H, Moura-Cordeiro JD, Santos LC, Mahecha GAB, Morais-Santos M, Oliveira CA
Prostate 2017 Jun;77(9):937-948.
PMID 28480526
 
Gene expression profiling of microdissected pancreatic ductal carcinomas using high-density DNA microarrays
Grützmann R, Pilarsky C, Ammerpohl O, Lüttges J, Böhme A, Sipos B, Foerder M, Alldinger I, Jahnke B, Schackert HK, Kalthoff H, Kremer B, Klöppel G, Saeger HD
Neoplasia Sep-Oct 2004;6(5):611-22.
PMID 15548371
 
Mitogenic effects of the up-regulation of minichromosome maintenance proteins in anaplastic thyroid carcinoma
Guida T, Salvatore G, Faviana P, Giannini R, Garcia-Rostan G, Provitera L, Basolo F, Fusco A, Carlomagno F, Santoro M
J Clin Endocrinol Metab 2005 Aug;90(8):4703-9.
PMID 15899946
 
Multiparameter analysis using cell cycle biomarkers for small-size lung adenocarcinoma: prognostic implications
Haruki T, Shomori K, Shiomi T, Taniguchi Y, Nakamura H, Ito H
Oncol Rep 2012 Sep;28(3):915-22.
PMID 22767360
 
Specific distribution patterns of hCDC47 expression in cutaneous diseases
Hiraiwa A, Fujita M, Adachi A, Ono H, Nagasaka T, Matsumoto Y, Ohashi M, Tomita Y, Ishibashi M
J Cutan Pathol 1998 Jul;25(6):285-90.
PMID 9694616
 
Deregulated minichromosomal maintenance protein MCM7 contributes to oncogene driven tumorigenesis
Honeycutt KA, Chen Z, Koster MI, Miers M, Nuchtern J, Hicks J, Roop DR, Shohet JM
Oncogene 2006 Jul 6;25(29):4027-32.
PMID 16518415
 
Minichromosome Maintenance (MCM) Family as potential diagnostic and prognostic tumor markers for human gliomas
Hua C, Zhao G, Li Y, Bie L
BMC Cancer 2014 Jul 21;14:526.
PMID 25046975
 
High expression of carbonic anhydrase IX is significantly associated with glandular lesions in gastroesophageal junction and with tumorigenesis markers BMI1, MCM4 and MCM7
Huber AR, Tan D, Sun J, Dean D, Wu T, Zhou Z
BMC Gastroenterol 2015 Jul 9;15:80.
PMID 26156831
 
How MCM loading and spreading specify eukaryotic DNA replication initiation sites
Hyrien O
F1000Res 2016 Aug 24;5:F1000 Faculty Rev-2063.
PMID 27635237
 
Involvement of c-myc-regulated genes in hepatocellular carcinoma related to genotype-C hepatitis B virus
Iizuka N, Tsunedomi R, Tamesa T, Okada T, Sakamoto K, Hamaguchi T, Yamada-Okabe H, Miyamoto T, Uchimura S, Hamamoto Y, Oka M
J Cancer Res Clin Oncol 2006 Jul;132(7):473-81.
PMID 16703398
 
Minichromosome maintenance protein 7 is a risk factor for recurrence in patients with Dukes C colorectal cancer
Ishibashi Y, Kinugasa T, Akagi Y, Ohchi T, Gotanda Y, Tanaka N, Fujino S, Yuge K, Kibe S, Yoshida N, Mizobe T, Oka Y, Yoshida T, Shirouzu K
Anticancer Res 2014 Aug;34(8):4569-75.
PMID 25075101
 
Regulation of MCM2-7 function
Ishimi Y
Genes Genet Syst 2018 Nov 10;93(4):125-133.
PMID 30369561
 
Expression of MCM-3 and MCM-7 in Primary Cutaneous T-cell Lymphomas
Jankowska-Konsur A, Kobierzycki C, Reich A, Grzegrzolka J, Maj J, Dziegiel P
Anticancer Res 2015 Nov;35(11):6017-26.
PMID 26504025
 
MCM7 serves as a prognostic marker in diffuse-type gastric adenocarcinoma and siRNA-mediated knockdown suppresses its oncogenic function
Kang W, Tong JH, Chan AW, Cheng AS, Yu J, To K
Oncol Rep 2014 May;31(5):2071-8.
PMID 24647462
 
Overexpression of CDT1 Is a Predictor of Poor Survival in Patients with Hepatocellular Carcinoma
Karavias D, Maroulis I, Papadaki H, Gogos C, Kakkos S, Karavias D, Bravou V
J Gastrointest Surg 2016 Mar;20(3):568-79.
PMID 26408331
 
A case study of human papillomavirus-associated bladder carcinoma developing after urethral condyloma acuminatum
Kawaguchi S, Shigehara K, Sasagawa T, Kuribayashi M, Junicho A, Hasegawa T, Maeda Y, Namiki M
Jpn J Clin Oncol 2012 May;42(5):455-8.
PMID 22416253
 
Diagnostic and prognostic value of cell-cycle regulatory genes in malignant thyroid neoplasms
Kebebew E, Peng M, Reiff E, Duh QY, Clark OH, McMillan A
World J Surg 2006 May;30(5):767-74.
PMID 16547620
 
Upregulated expression of BCL2, MCM7, and CCNE1 indicate cisplatin-resistance in the set of two human bladder cancer cell lines: T24 cisplatin sensitive and T24R2 cisplatin resistant bladder cancer cell lines
Kim SH, Ho JN, Jin H, Lee SC, Lee SE, Hong SK, Lee JW, Lee ES, Byun SS
Investig Clin Urol 2016 Jan;57(1):63-72.
PMID 26966728
 
Comparison of minichromosome maintenance proteins (MCM-3, MCM-7) and metallothioneins (MT-I/II, MT-III) expression in relation to clinicopathological data in ovarian cancer
Kobierzycki C, Pula B, Skiba M, Jablonska K, Latkowski K, Zabel M, Nowak-Markwitz E, Spaczynski M, Kedzia W, Podhorska-Okolow M, Dziegiel P
Anticancer Res 2013 Dec;33(12):5375-83.
PMID 24324072
 
Direct regulation of the minichromosome maintenance complex by MYCN in neuroblastoma
Koppen A, Ait-Aissa R, Koster J, van Sluis PG, Ora I, Caron HN, Volckmann R, Versteeg R, Valentijn LJ
Eur J Cancer 2007 Nov;43(16):2413-22.
PMID 17826980
 
Expression of proliferative biomarkers in anal intraepithelial neoplasia of HIV-positive men
Kreuter A, Jesse M, Potthoff A, Brockmeyer NH, Gambichler T, Stücker M, Bechara FG, Pfister H, Wieland U
J Am Acad Dermatol 2010 Sep;63(3):490-8.
PMID 20006407
 
Human papillomavirus oncoprotein E6 binds to the C-terminal region of human minichromosome maintenance 7 protein
Kukimoto I, Aihara S, Yoshiike K, Kanda T
Biochem Biophys Res Commun 1998 Aug 10;249(1):258-62.
PMID 9705868
 
EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients
Laitinen S, Martikainen PM, Tolonen T, Isola J, Tammela TL, Visakorpi T
Int J Cancer 2008 Feb 1;122(3):595-602.
PMID 17943722
 
Minichromosome maintenance proteins 2, 3 and 7 in medulloblastoma: overexpression and involvement in regulation of cell migration and invasion
Lau KM, Chan QK, Pang JC, Li KK, Yeung WW, Chung NY, Lui PC, Tam YS, Li HM, Zhou L, Wang Y, Mao Y, Ng HK
Oncogene 2010 Oct 7;29(40):5475-89.
PMID 20661220
 
MCM7 polymorphisms associated with the AML relapse and overall survival
Lee JS, Cheong HS, Koh Y, Ahn KS, Shin HD, Yoon SS
Ann Hematol 2017 Jan;96(1):93-98.
PMID 27837251
 
Evaluation of AIbZIP and Cdc47 as markers for human prostatic diseases
Levesque MH, El-Alfy M, Berger L, Labrie F, Labrie C
Urology 2007 Jan;69(1):196-201.
PMID 17270658
 
Replicative MCM7 protein as a proliferation marker in endometrial carcinoma: a tissue microarray and clinicopathological analysis
Li SS, Xue WC, Khoo US, Ngan HY, Chan KY, Tam IY, Chiu PM, Ip PP, Tam KF, Cheung AN
Histopathology 2005 Mar;46(3):307-13.
PMID 15720416
 
Identification of genomic alterations in pancreatic cancer using array-based comparative genomic hybridization
Liang JW, Shi ZZ, Shen TY, Che X, Wang Z, Shi SS, Xu X, Cai Y, Zhao P, Wang CF, Zhou ZX, Wang MR
PLoS One 2014 Dec 11;9(12):e114616.
PMID 25502777
 
Simvastatin suppresses the DNA replication licensing factor MCM7 and inhibits the growth of tamoxifen-resistant breast cancer cells
Liang Z, Li W, Liu J, Li J, He F, Jiang Y, Yang L, Li P, Wang B, Wang Y, Ren Y, Yang J, Luo Z, Vaziri C, Liu P
Sci Rep 2017 Feb 2;7:41776.
PMID 28150753
 
Prognostic value of minichromosome maintenance mRNA expression in early-stage pancreatic ductal adenocarcinoma patients after pancreaticoduodenectomy
Liao X, Han C, Wang X, Huang K, Yu T, Yang C, Huang R, Liu Z, Han Q, Peng T
Cancer Manag Res 2018 Sep 5;10:3255-3271.
PMID 30233242
 
Distinct Diagnostic and Prognostic Values of Minichromosome Maintenance Gene Expression in Patients with Hepatocellular Carcinoma
Liao X, Liu X, Yang C, Wang X, Yu T, Han C, Huang K, Zhu G, Su H, Qin W, Huang R, Yu L, Deng J, Zeng X, Ye X, Peng T
J Cancer 2018 Jun 12;9(13):2357-2373.
PMID 30026832
 
Identification of key genes and long non-coding RNA associated ceRNA networks in hepatocellular carcinoma
Liu J, Li W, Zhang J, Ma Z, Wu X, Tang L
PeerJ 2019 Nov 1;7:e8021.
PMID 31695969
 
Biological effects of lentivirus-mediated silencing of minichromosome maintenance protein 7 with shRNA on the liver cancer MHCC-97H cells
Liu J, Tian L, Chen BA, Xia JR
Int J Clin Exp Med 2015 Jun 15;8(6):8433-41.
PMID 26309496
 
A genetic variant in the promoter region of miR-106b-25 cluster and risk of HBV infection and hepatocellular carcinoma
Liu Y, Zhang Y, Wen J, Liu L, Zhai X, Liu J, Pan S, Chen J, Shen H, Hu Z
PLoS One 2012;7(2):e32230.
PMID 22393390
 
A panel of protein markers for the early detection of lung cancer with bronchial brushing specimens
Liu YZ, Jiang YY, Wang BS, Hao JJ, Shang L, Zhang TT, Cao J, Xu X, Zhan QM, Wang MR
Cancer Cytopathol 2014 Nov;122(11):833-41.
PMID 25045014
 
MCM7 and its hosted miR-25, 93 and 106b cluster elicit YAP/TAZ oncogenic activity in lung cancer
Lo Sardo F, Forcato M, Sacconi A, Capaci V, Zanconato F, Di Agostino S, Del Sal G, Pandolfi PP, Strano S, Bicciato S, Blandino G
Carcinogenesis 2017 Jan;38(1):64-75.
PMID 27797825
 
Novel Biomarker Candidates for Colorectal Cancer Metastasis: A Meta-analysis of In Vitro Studies
Long NP, Lee WJ, Huy NT, Lee SJ, Park JH, Kwon SW
Cancer Inform 2016 Sep 22;15(Suppl 4):11-7.
PMID 27688707
 
Expression of 11β-hydroxysteroid dehydrogenase type 1 in breast cancer and adjacent non-malignant tissue. An immunocytochemical study
Lu L, Zhao G, Luu-The V, Ouellet J, Fan Z, Labrie F, Pelletier G
Pathol Oncol Res 2011 Sep;17(3):627-32.
PMID 21267686
 
Lamin B2 binding to minichromosome maintenance complex component 7 promotes non-small cell lung carcinogenesis
Ma Y, Fei L, Zhang M, Zhang W, Liu X, Wang C, Luo Y, Zhang H, Han Y
Oncotarget 2017 Aug 18;8(62):104813-104830.
PMID 29285216
 
Regulation of minichromosome maintenance gene family by microRNA-1296 and genistein in prostate cancer
Majid S, Dar AA, Saini S, Chen Y, Shahryari V, Liu J, Zaman MS, Hirata H, Yamamura S, Ueno K, Tanaka Y, Dahiya R
Cancer Res 2010 Apr 1;70(7):2809-18.
PMID 20332239
 
Immunohistochemical expression and prognostic significance of CCND3, MCM2 and MCM7 in Hodgkin lymhoma
Marnerides A, Vassilakopoulos TP, Boltetsou E, Levidou G, Angelopoulou MK, Thymara I, Kyrtsonis MC, Pappi V, Tsopra O, Panayiotidis P, Pangalis GA, Beris P, Patsouris E, Korkolopoulou P
Anticancer Res 2011 Oct;31(10):3585-94.
PMID 21965782
 
Relationships between cell cycle pathway gene polymorphisms and risk of hepatocellular carcinoma
Nan YL, Hu YL, Liu ZK, Duan FF, Xu Y, Li S, Li T, Chen DF, Zeng XY
World J Gastroenterol 2016 Jun 28;22(24):5558-67.
PMID 27350734
 
Minichromosome maintenance protein 7 in colorectal cancer: implication of prognostic significance
Nishihara K, Shomori K, Fujioka S, Tokuyasu N, Inaba A, Osaki M, Ogawa T, Ito H
Int J Oncol 2008 Aug;33(2):245-51.
PMID 18636144
 
Correlation between levels of expression of minichromosome maintenance proteins, Ki-67 proliferation antigen and metallothionein I/II in laryngeal squamous cell cancer
Nowinska K, Chmielewska M, Piotrowska A, Pula B, Pastuszewski W, Krecicki T, Podhorska-Okońow M, Zabel M, Dziegiel P
Int J Oncol 2016 Feb;48(2):635-45.
PMID 26648405
 
Minichromosome maintenance protein 7 as a potential prognostic factor for progression-free survival in high-grade serous carcinomas of the ovary
Ota T, Clayton AC, Minot DM, Shridhar V, Hartmann LC, Gilks CB, Chien JR
Mod Pathol 2011 Feb;24(2):277-87.
PMID 21076460
 
DNA replication regulation protein Mcm7 as a marker of proliferation in prostate cancer
Padmanabhan V, Callas P, Philips G, Trainer TD, Beatty BG
J Clin Pathol 2004 Oct;57(10):1057-62.
PMID 15452160
 
A 'DNA replication' signature of progression and negative outcome in colorectal cancer
Pillaire MJ, Selves J, Gordien K, Gourraud PA, Gentil C, Danjoux M, Do C, Negre V, Bieth A, Guimbaud R, Trouche D, Pasero P, Méchali M, Hoffmann JS, Cazaux C
Oncogene 2010 Feb 11;29(6):876-87.
PMID 19901968
 
MCM7 amplification and overexpression promote cell proliferation, colony formation and migration in esophageal squamous cell carcinoma by activating the AKT1/mTOR signaling pathway
Qiu YT, Wang WJ, Zhang B, Mei LL, Shi ZZ
Oncol Rep 2017 Jun;37(6):3590-3596.
PMID 28498460
 
MCM7 promotes cancer progression through cyclin D1-dependent signaling and serves as a prognostic marker for patients with hepatocellular carcinoma
Qu K, Wang Z, Fan H, Li J, Liu J, Li P, Liang Z, An H, Jiang Y, Lin Q, Dong X, Liu P, Liu C
Cell Death Dis 2017 Feb 9;8(2):e2603.
PMID 28182015
 
MCM7 amplification and overexpression are associated with prostate cancer progression
Ren B, Yu G, Tseng GC, Cieply K, Gavel T, Nelson J, Michalopoulos G, Yu YP, Luo JH
Oncogene 2006 Feb 16;25(7):1090-8.
PMID 16247466
 
Comparative protein profiling reveals minichromosome maintenance (MCM) proteins as novel potential tumor markers for meningiomas
Saydam O, Senol O, Schaaij-Visser TB, Pham TV, Piersma SR, Stemmer-Rachamimov AO, Wurdinger T, Peerdeman SM, Jimenez CR
J Proteome Res 2010 Jan;9(1):485-94.
PMID 19877719
 
Identification of genes involved in the four stages of colorectal cancer: Gene expression profiling
Shi G, Wang Y, Zhang C, Zhao Z, Sun X, Zhang S, Fan J, Zhou C, Zhang J, Zhang H, Liu J
Mol Cell Probes 2018 Feb;37:39-47.
PMID 29179987
 
Inhibition of prostate cancer growth and metastasis using small interference RNA specific for minichromosome complex maintenance component 7
Shi YK, Yu YP, Tseng GC, Luo JH
Cancer Gene Ther 2010 Oct;17(10):694-9.
PMID 20539323
 
Etiologic role of human papillomavirus infection in bladder carcinoma
Shigehara K, Sasagawa T, Kawaguchi S, Nakashima T, Shimamura M, Maeda Y, Konaka H, Mizokami A, Koh E, Namiki M
Cancer 2011 May 15;117(10):2067-76.
PMID 21523718
 
Minichromosome maintenance protein MCM7 is a direct target of the MYCN transcription factor in neuroblastoma
Shohet JM, Hicks MJ, Plon SE, Burlingame SM, Stuart S, Chen SY, Brenner MK, Nuchtern JG
Cancer Res 2002 Feb 15;62(4):1123-8.
PMID 11861392
 
Expression of MYCN in pediatric synovial sarcoma
Somers GR, Zielenska M, Abdullah S, Sherman C, Chan S, Thorner PS
Mod Pathol 2007 Jul;20(7):734-41.
PMID 17464317
 
Expression of aromatase and 17beta-hydroxysteroid dehydrogenase types 1, 7 and 12 in breast cancer. An immunocytochemical study
Song D, Liu G, Luu-The V, Zhao D, Wang L, Zhang H, Xueling G, Li S, Désy L, Labrie F, Pelletier G
J Steroid Biochem Mol Biol 2006 Oct;101(2-3):136-44.
PMID 16930994
 
Identification of biomarkers that distinguish human papillomavirus (HPV)-positive versus HPV-negative head and neck cancers in a mouse model
Strati K, Pitot HC, Lambert PF
Proc Natl Acad Sci U S A 2006 Sep 19;103(38):14152-7.
PMID 16959885
 
Cloning and characterization of human MCM7 promoter
Suzuki S, Adachi A, Hiraiwa A, Ohashi M, Ishibashi M, Kiyono T
Gene 1998 Aug 17;216(1):85-91.
PMID 9714754
 
Minichromosome maintenance-7 and geminin are reliable prognostic markers in patients with oral squamous cell carcinoma: immunohistochemical study
Tamura T, Shomori K, Haruki T, Nosaka K, Hamamoto Y, Shiomi T, Ryoke K, Ito H
J Oral Pathol Med 2010 Apr;39(4):328-34.
PMID 20136698
 
RNAi-mediated knockdown of MCM7 gene on CML cells and its therapeutic potential for leukemia
Tian L, Liu J, Xia GH, Chen BA
Med Oncol 2017 Feb;34(2):21.
PMID 28058629
 
Histopathological variables and biomarkers enhancer of zeste homologue 2, Ki-67 and minichromosome maintenance protein 7 as prognosticators in primarily endocrine-treated prostate cancer
Tolonen TT, Tammela TL, Kujala PM, Tuominen VJ, Isola JJ, Visakorpi T
BJU Int 2011 Nov;108(9):1430-8.
PMID 21592298
 
Minichromosome Maintenance Protein 7 is a potential therapeutic target in human cancer and a novel prognostic marker of non-small cell lung cancer
Toyokawa G, Masuda K, Daigo Y, Cho HS, Yoshimatsu M, Takawa M, Hayami S, Maejima K, Chino M, Field HI, Neal DE, Tsuchiya E, Ponder BA, Maehara Y, Nakamura Y, Hamamoto R
Mol Cancer 2011 May 28;10:65.
PMID 21619671
 
Modelling the Effects of MCM7 Variants, Somatic Mutations, and Clinical Features on Acute Myeloid Leukemia Susceptibility and Prognosis
Tripon F, Iancu M, Trifa A, Crauciuc GA, Boglis A, Dima D, Lazar E, Banescu C
J Clin Med 2020 Jan 8;9(1):158.
PMID 31936215
 
Correlation of MYCN amplification with MCM7 protein expression in neuroblastomas: a chromogenic in situ hybridization study in paraffin sections
Tsai HY, Hsi BL, Hung IJ, Yang CP, Lin JN, Chen JC, Tsai SF, Huang SF
Hum Pathol 2004 Nov;35(11):1397-403.
PMID 15668898
 
MicroRNA-106b~25 cluster is upregulated in relapsed MLL-rearranged pediatric acute myeloid leukemia
Verboon LJ, Obulkasim A, de Rooij JD, Katsman-Kuipers JE, Sonneveld E, Baruchel A, Trka J, Reinhardt D, Pieters R, Cloos J, Kaspers GJ, Klusmann JH, Zwaan CM, Fornerod M, van den Heuvel-Eibrink MM
Oncotarget 2016 Jul 26;7(30):48412-48422.
PMID 27351222
 
Critical genes in head and neck squamous cell carcinoma revealed by bioinformatic analysis of gene expression data
Wang B, Wang T, Cao XL, Li Y
Genet Mol Res 2015 Dec 21;14(4):17406-15.
PMID 26782382
 
Arsenic trioxide inhibits liver cancer stem cells and metastasis by targeting SRF/MCM7 complex
Wang HY, Zhang B, Zhou JN, Wang DX, Xu YC, Zeng Q, Jia YL, Xi JF, Nan X, He LJ, Yue W, Pei XT
Cell Death Dis 2019 Jun 11;10(6):453.
PMID 31186405
 
Expression and prognostic significance of MCM-3 and MCM-7 in salivary adenoid cystic carcinoma
Wen QL, Zhu SM, Jiang LH, Xiang FY, Yin WJ, Qian YY, Huang YQ, Yin KX, Zhu X, Ge MH
Int J Clin Exp Pathol 2018 Nov 1;11(11):5359-5369.
PMID 31949617
 
MCM7 expression is a promising predictor of recurrence in patients surgically resected for meningiomas
Winther TL, Torp SH
J Neurooncol 2017 Feb;131(3):575-583.
PMID 27868157
 
Transcription regulation network analysis of MCF7 breast cancer cells exposed to estradiol
Wu JZ, Lu P, Liu R, Yang TJ
Asian Pac J Cancer Prev 2012;13(8):3681-5.
PMID 23098454
 
Seven-senescence-associated gene signature predicts overall survival for Asian patients with hepatocellular carcinoma
Xiang XH, Yang L, Zhang X, Ma XH, Miao RC, Gu JX, Fu YN, Yao Q, Zhang JY, Liu C, Lin T, Qu K
World J Gastroenterol 2019 Apr 14;25(14):1715-1728.
PMID 31011256
 
Histone deacetylase inhibitor SAHA epigenetically regulates miR-17-92 cluster and MCM7 to upregulate MICA expression in hepatoma
Yang H, Lan P, Hou Z, Guan Y, Zhang J, Xu W, Tian Z, Zhang C
Br J Cancer 2015 Jan 6;112(1):112-21.
PMID 25393367
 
Identification of candidate cancer genes involved in human retinoblastoma by data mining
Yang J, Zhao JJ, Zhu Y, Xiong W, Lin JY, Ma X
Childs Nerv Syst 2008 Aug;24(8):893-900.
PMID 18350306
 
The Expression of MCM7 is a Useful Biomarker in the Early Diagnostic of Gastric Cancer
Yang JY, Li D, Zhang Y, Guan BX, Gao P, Zhou XC, Zhou CJ
Pathol Oncol Res 2018 Apr;24(2):367-372.
PMID 28540486
 
miR-106b promotes cancer progression in hepatitis B virus-associated hepatocellular carcinoma
Yen CS, Su ZR, Lee YP, Liu IT, Yen CJ
World J Gastroenterol 2016 Jun 14;22(22):5183-92.
PMID 27298561
 
Regulation of Geminin and Cdt1 expression by E2F transcription factors
Yoshida K, Inoue I
Oncogene 2004 May 6;23(21):3802-12.
PMID 14990995
 
Five Novel Oncogenic Signatures Could Be Utilized as AFP-Related Diagnostic Biomarkers for Hepatocellular Carcinoma Based on Next-Generation Sequencing
Yu Z, Wang R, Chen F, Wang J, Huang X
Dig Dis Sci 2018 Apr;63(4):945-957.
PMID 29442275
 
Cantharidin modulates the E2F1/MCM7-miR-106b-93/p21-PTEN signaling axis in MCF-7 breast cancer cells
Zhang H, Yan X
Oncol Lett 2015 Nov;10(5):2849-2855.
PMID 26722252
 
The protein levels of MCM7 and p63 in evaluating lesion severity of cervical disease
Zhang J, Wang L, Qiu M, Liu Z, Qian W, Yang Y, Wu S, Feng Y
Int J Gynecol Cancer 2013 Feb;23(2):318-24.
PMID 23318911
 
TSA suppresses miR-106b-93-25 cluster expression through downregulation of MYC and inhibits proliferation and induces apoptosis in human EMC
Zhao ZN, Bai JX, Zhou Q, Yan B, Qin WW, Jia LT, Meng YL, Jin BQ, Yao LB, Wang T, Yang AG
PLoS One 2012;7(9):e45133.
PMID 23028803
 
Expression of minichromosome maintenance genes in renal cell carcinoma
Zhong H, Chen B, Neves H, Xing J, Ye Y, Lin Y, Zhuang G, Zhang SD, Huang J, Kwok HF
Cancer Manag Res 2017 Nov 15;9:637-647.
PMID 29180899
 
Overexpression of G9a and MCM7 in oesophageal squamous cell carcinoma is associated with poor prognosis
Zhong X, Chen X, Guan X, Zhang H, Ma Y, Zhang S, Wang E, Zhang L, Han Y
Histopathology 2015 Jan;66(2):192-200.
PMID 24805087
 
Aberrant expression of NEK2 and its clinical significance in non-small cell lung cancer
Zhong X, Guan X, Liu W, Zhang L
Oncol Lett 2014 Oct;8(4):1470-1476.
PMID 25202351
 
MCM7 expression predicts post-operative prognosis for hepatocellular carcinoma
Zhou YM, Zhang XF, Cao L, Li B, Sui CJ, Li YM, Yin ZF
Liver Int 2012 Nov;32(10):1505-9.
PMID 22784096
 
Identification of Protein Abundance Changes in Hepatocellular Carcinoma Tissues Using PCT-SWATH
Zhu Y, Zhu J, Lu C, Zhang Q, Xie W, Sun P, Dong X, Yue L, Sun Y, Yi X, Zhu T, Ruan G, Aebersold R, Huang S, Guo T
Proteomics Clin Appl 2019 Jan;13(1):e1700179.
PMID 30365225
 
Array comparative genomic hybridization, expression array, and protein analysis of critical regions on chromosome arms 1q, 7q, and 8p in adenocarcinomas of the gastroesophageal junction
van Dekken H, Tilanus HW, Hop WC, Dinjens WN, Wink JC, Vissers KJ, van Marion R
Cancer Genet Cytogenet 2009 Feb;189(1):37-42.
PMID 19167610
 

Citation

This paper should be referenced as such :
Lima K, Rego EM, Machado-Neto JA
MCM7 (minichromosome maintenance complex component 7);
Atlas Genet Cytogenet Oncol Haematol. in press


External links

 

Nomenclature
HGNC (Hugo)MCM7   6950
Cards
AtlasMCM7ID41323ch7q22
Entrez_Gene (NCBI)MCM7    minichromosome maintenance complex component 7
AliasesCDC47; MCM2; P1.1-MCM3; P1CDC47; 
P85MCM; PNAS146; PPP1R104
GeneCards (Weizmann)MCM7
Ensembl hg19 (Hinxton)ENSG00000166508 [Gene_View]
Ensembl hg38 (Hinxton)ENSG00000166508 [Gene_View]  ENSG00000166508 [Sequence]  chr7:100092728-100100780 [Contig_View]  MCM7 [Vega]
ICGC DataPortalENSG00000166508
TCGA cBioPortalMCM7
AceView (NCBI)MCM7
Genatlas (Paris)MCM7
SOURCE (Princeton)MCM7
Genetics Home Reference (NIH)MCM7
Genomic and cartography
GoldenPath hg38 (UCSC)MCM7  -     chr7:100092728-100100780 -  7q22.1   [Description]    (hg38-Dec_2013)
GoldenPath hg19 (UCSC)MCM7  -     7q22.1   [Description]    (hg19-Feb_2009)
GoldenPathMCM7 - 7q22.1 [CytoView hg19]  MCM7 - 7q22.1 [CytoView hg38]
ImmunoBaseENSG00000166508
Genome Data Viewer NCBIMCM7 [Mapview hg19]  
OMIM600592   
Gene and transcription
Genbank (Entrez)AF279900 AI083651 AK055379 AK096959 AK226175
RefSeq transcript (Entrez)NM_001278595 NM_005916 NM_182776
Consensus coding sequences : CCDS (NCBI)MCM7
Gene ExpressionMCM7 [ NCBI-GEO ]   MCM7 [ EBI - ARRAY_EXPRESS ]   MCM7 [ SEEK ]   MCM7 [ MEM ]
Gene Expression Viewer (FireBrowse)MCM7 [ Firebrowse - Broad ]
GenevisibleExpression of MCM7 in : [tissues]  [cell-lines]  [cancer]  [perturbations]  
BioGPS (Tissue expression)4176
GTEX Portal (Tissue expression)MCM7
Human Protein AtlasENSG00000166508-MCM7 [pathology]   [cell]   [tissue]
Protein : pattern, domain, 3D structure
UniProt/SwissProtP33993   [function]  [subcellular_location]  [family_and_domains]  [pathology_and_biotech]  [ptm_processing]  [expression]  [interaction]
NextProtP33993  [Sequence]  [Exons]  [Medical]  [Publications]
With graphics : InterProP33993
Catalytic activity : Enzyme3.6.4.12 [ Enzyme-Expasy ]   3.6.4.123.6.4.12 [ IntEnz-EBI ]   3.6.4.12 [ BRENDA ]   3.6.4.12 [ KEGG ]   [ MEROPS ]
PhosPhoSitePlusP33993
Domaine pattern : Prosite (Expaxy)MCM_1 (PS00847)    MCM_2 (PS50051)   
Domains : Interpro (EBI)AAA+_ATPase    MCM    MCM7    MCM_CS    MCM_dom    MCM_lid    MCM_N    MCM_OB    NA-bd_OB-fold    P-loop_NTPase   
Domain families : Pfam (Sanger)MCM (PF00493)    MCM_lid (PF17855)    MCM_N (PF14551)    MCM_OB (PF17207)   
Domain families : Pfam (NCBI)pfam00493    pfam17855    pfam14551    pfam17207   
Domain families : Smart (EMBL)AAA (SM00382)  MCM (SM00350)  
Conserved Domain (NCBI)MCM7
PDB (RSDB)6XTX    6XTY   
PDB Europe6XTX    6XTY   
PDB (PDBSum)6XTX    6XTY   
PDB (IMB)6XTX    6XTY   
Structural Biology KnowledgeBase6XTX    6XTY   
SCOP (Structural Classification of Proteins)6XTX    6XTY   
CATH (Classification of proteins structures)6XTX    6XTY   
SuperfamilyP33993
AlphaFold pdb e-kbP33993   
Human Protein Atlas [tissue]ENSG00000166508-MCM7 [tissue]
HPRD01154
Protein Interaction databases
DIP (DOE-UCLA)P33993
IntAct (EBI)P33993
Complex Portal (EBI)P33993 CPX-2940 MCM complex
BioGRIDMCM7
STRING (EMBL)MCM7
ZODIACMCM7
Ontologies - Pathways
QuickGOP33993
Ontology : AmiGOdouble-strand break repair via break-induced replication  chromosome, telomeric region  chromatin  DNA binding  DNA helicase activity  DNA replication origin binding  single-stranded DNA binding  protein binding  ATP binding  nucleus  nucleus  nucleoplasm  nucleoplasm  nucleolus  cytosol  DNA replication  pre-replicative complex assembly involved in nuclear cell cycle DNA replication  DNA unwinding involved in DNA replication  DNA replication initiation  DNA replication initiation  DNA strand elongation involved in DNA replication  cellular response to DNA damage stimulus  cell population proliferation  membrane  hydrolase activity  pre-replicative complex assembly  regulation of phosphorylation  response to drug  MCM complex  MCM complex  MCM complex  CMG complex  cellular response to epidermal growth factor stimulus  cellular response to xenobiotic stimulus  single-stranded 3'-5' DNA helicase activity  
Ontology : EGO-EBIdouble-strand break repair via break-induced replication  chromosome, telomeric region  chromatin  DNA binding  DNA helicase activity  DNA replication origin binding  single-stranded DNA binding  protein binding  ATP binding  nucleus  nucleus  nucleoplasm  nucleoplasm  nucleolus  cytosol  DNA replication  pre-replicative complex assembly involved in nuclear cell cycle DNA replication  DNA unwinding involved in DNA replication  DNA replication initiation  DNA replication initiation  DNA strand elongation involved in DNA replication  cellular response to DNA damage stimulus  cell population proliferation  membrane  hydrolase activity  pre-replicative complex assembly  regulation of phosphorylation  response to drug  MCM complex  MCM complex  MCM complex  CMG complex  cellular response to epidermal growth factor stimulus  cellular response to xenobiotic stimulus  single-stranded 3'-5' DNA helicase activity  
Pathways : BIOCARTACDK Regulation of DNA Replication [Genes]   
Pathways : KEGGDNA replication    Cell cycle   
REACTOMEP33993 [protein]
REACTOME PathwaysR-HSA-69052 [pathway]   
NDEx NetworkMCM7
Atlas of Cancer Signalling NetworkMCM7
Wikipedia pathwaysMCM7
Orthology - Evolution
OrthoDB4176
GeneTree (enSembl)ENSG00000166508
Phylogenetic Trees/Animal Genes : TreeFamMCM7
Homologs : HomoloGeneMCM7
Homology/Alignments : Family Browser (UCSC)MCM7
Gene fusions - Rearrangements
Fusion : MitelmanZNF3::MCM7 [7q22.1/7q22.1]  
Fusion : QuiverMCM7
Polymorphisms : SNP and Copy number variants
NCBI Variation ViewerMCM7 [hg38]
dbSNP Single Nucleotide Polymorphism (NCBI)MCM7
dbVarMCM7
ClinVarMCM7
MonarchMCM7
1000_GenomesMCM7 
Exome Variant ServerMCM7
GNOMAD BrowserENSG00000166508
Varsome BrowserMCM7
ACMGMCM7 variants
VarityP33993
Genomic Variants (DGV)MCM7 [DGVbeta]
DECIPHERMCM7 [patients]   [syndromes]   [variants]   [genes]  
CONAN: Copy Number AnalysisMCM7 
Mutations
ICGC Data PortalMCM7 
TCGA Data PortalMCM7 
Broad Tumor PortalMCM7
OASIS PortalMCM7 [ Somatic mutations - Copy number]
Somatic Mutations in Cancer : COSMICMCM7  [overview]  [genome browser]  [tissue]  [distribution]  
Somatic Mutations in Cancer : COSMIC3DMCM7
Mutations and Diseases : HGMDMCM7
LOVD (Leiden Open Variation Database)[gene] [transcripts] [variants]
BioMutaMCM7
DgiDB (Drug Gene Interaction Database)MCM7
DoCM (Curated mutations)MCM7
CIViC (Clinical Interpretations of Variants in Cancer)MCM7
NCG (London)MCM7
Cancer3DMCM7
Impact of mutations[PolyPhen2] [Provean] [Buck Institute : MutDB] [Mutation Assessor] [Mutanalyser]
Diseases
OMIM600592   
Orphanet
DisGeNETMCM7
MedgenMCM7
Genetic Testing Registry MCM7
NextProtP33993 [Medical]
GENETestsMCM7
Target ValidationMCM7
Huge Navigator MCM7 [HugePedia]
ClinGenMCM7
Clinical trials, drugs, therapy
MyCancerGenomeMCM7
Protein Interactions : CTDMCM7
Pharm GKB GenePA30697
PharosP33993
Clinical trialMCM7
Miscellaneous
canSAR (ICR)MCM7
HarmonizomeMCM7
DataMed IndexMCM7
Probes
Litterature
PubMed290 Pubmed reference(s) in Entrez
GeneRIFsGene References Into Functions (Entrez)
EVEXMCM7
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Fri Oct 8 21:21:57 CEST 2021

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.